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Abstract
Background: Human Artificial Chromosomes (HACs) are potentially useful vectors for gene
transfer studies and for functional annotation of the genome because of their suitability for cloning,
manipulating and transferring large segments of the genome. However, development of HACs for
the transfer of large genomic loci into mammalian cells has been limited by difficulties in
manipulating high-molecular weight DNA, as well as by the low overall frequencies of de novo HAC
formation. Indeed, to date, only a small number of large (>100 kb) genomic loci have been reported
to be successfully packaged into de novo HACs.
Results: We have developed novel methodologies to enable efficient assembly of HAC vectors
containing any genomic locus of interest. We report here the creation of a novel, bimolecular
system based on bacterial artificial chromosomes (BACs) for the construction of HACs
incorporating any defined genomic region. We have utilized this vector system to rapidly design,
construct and validate multiple de novo HACs containing large (100–200 kb) genomic loci including
therapeutically significant genes for human growth hormone (HGH), polycystic kidney disease
(PKD1) and ß-globin. We report significant differences in the ability of different genomic loci to
support de novo HAC formation, suggesting possible effects of cis-acting genomic elements. Finally,
as a proof of principle, we have observed sustained ß-globin gene expression from HACs
incorporating the entire 200 kb ß-globin genomic locus for over 90 days in the absence of selection.
Conclusion: Taken together, these results are significant for the development of HAC vector
technology, as they enable high-throughput assembly and functional validation of HACs containing
any large genomic locus. We have evaluated the impact of different genomic loci on the frequency
of HAC formation and identified segments of genomic DNA that appear to facilitate de novo HAC
formation. These genomic loci may be useful for identifying discrete functional elements that may
be incorporated into future generations of HAC vectors.
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Background
Human artificial chromosomes are currently being devel-
oped as tools for functional annotation of the genome
and as potential vectors for gene therapy and other bio-
technological applications (reviewed in [1,2]). Strategies
for the creation of artificial or engineered chromosomes
can be broadly divided into two classes: top down, based
on the truncation of an existing chromosome into a much
smaller mini-chromosome suitable for further manipula-
tion, and bottom up, whereby defined, cloned chromo-
somal elements are assembled in vitro into a prefabricated
unit that is capable of nucleating formation of a HAC de
novo  upon introduction into human cells [1-4]. These
cloned chromosomal elements may also be assembled in
cultured cells through a combination of non-homologous
recombination and end-joining mechanisms [5]. Thus far,
both approaches have resulted in the creation of a de novo
HAC composed of large concatamers of the input DNA
species (reviewed in [2]). These de novo HACs are mitoti-
cally stable in the absence of selection, associate with key
centromere and kinetochore proteins and are functionally
comparable to the native chromosomes of the host cell.
Furthermore, HACs containing two genomic loci, for
HPRT and GCH1, have demonstrated evidence of func-
tionality in certain cell culture models, establishing the
potential application of HACs as vectors for gene transfer
[6-8].
Creation of artificial chromosomes de novo minimally
requires a cloned centromeric element of either natural
[9] or synthetic [5] origin. Only higher-order alpha-satel-
lite DNA, found at the centromeres of all normal human
chromosomes [10], has been shown to be capable of
nucleating centromere formation de novo. Alpha-satellite
DNA consists of a hierarchical structure of tandem repeti-
tive monomers of ~170 bp, which may be further organ-
ized into higher-order repeat units over many hundreds of
kilobases [11]. Higher-order alpha-satellite DNA is capa-
ble of establishing the assembly of a protein/DNA com-
plex, the kinetochore, which mediates the interactions
between the chromosome and the spindle apparatus dur-
ing cell division [12,13]. These and other lines of evidence
suggest that alpha-satellite DNA of this type represents the
functional centromere in normal human chromosomes
[10,14].
In addition to a functioning centromere, linear artificial
chromosomes require synthetic telomeres, which are
capable of seeding large telomeric arrays in vivo [15].
However, telomeric DNA is not required for the creation
of circular HACs de novo, and its presence or absence
appears to have no significant impact on the stability of
such HACs [16].
Finally, HAC vectors require origins of DNA replication
that are functionally analogous to Autonomously Repli-
cating Sequence (ARS) elements in yeast [17]. However,
mammalian origins of replication remain poorly defined
[18], although at least some mammalian origin elements
("replicators") have been documented that continue to
behave as such when translocated to an ectopic chromo-
somal location [19,20]. Notwithstanding uncertainty
about the genomic features that constitute an origin,
mammalian origins of replication have been shown to
occur on average once every ~100 kb [21,22]. De novo
HAC formation at frequencies of at least 10% has been
documented from BAC vectors containing only cloned
alpha-satellite DNA [2-4,16], implying that replication
origin function must be supplied by elements within
alpha-satellite or the BAC vector backbone. Notwith-
standing this result, we reasoned that we could augment
de novo HAC formation by providing any genomic frag-
ment of at least 100 kb in cis to the centromeric element
of the HAC vector, thereby providing additional origin
function and potentially additional unidentified func-
tional elements, or simply by providing improved stabil-
ity as a consequence of an increase in the size of the HAC
vector.
To circumvent technical difficulties in the manipulation
of high-molecular weight DNA by traditional cloning
techniques [23], we have developed a novel transposition-
based approach to rapidly retrofit genomic BAC clones
with telomeres and other key functional elements. Liga-
tion of the linearized derivatives of these retrofitted BAC
vectors (referred to as "BAC-GEN" vectors) with a comple-
mentary linearized BAC vector containing a synthetic
D17Z1 alpha-satellite array [5,24] and a telomere
(referred to as "BAC-CEN") results in the assembly of a
linear prefabricated HAC vector containing the defined
genomic fragment of interest. Here, we apply this method
to the construction and validation of HAC vectors con-
taining different large fragments from the human
genome, representing a diverse group of functionally val-
idated de novo HACs containing human genes.
In the course of this work, we observed that certain
genomic loci appear to greatly facilitate the formation of
de novo HACs, suggesting the existence of at least one addi-
tional parameter to be optimized during the development
of future iterations of HAC vectors. Such loci may contain
origins of replication [20,25], scaffold or matrix attach-
ment regions (S/MARs) [26] or other functionally signifi-
cant chromosomal elements that might contribute to
HAC formation and/or stability. We have applied this
approach to the construction of a prefabricated HAC vec-
tor incorporating the entire 200 kb ß-globin genomic
locus, which contains a well-defined mammalian origin
of replication [20]. We demonstrate efficient rates ofBMC Biotechnology 2005, 5:21 http://www.biomedcentral.com/1472-6750/5/21
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formation of these ß-globin HACs and provide evidence
of persistent gene expression. Taken together, the ability
to rapidly create multiple, functionally validated BAC-
based HAC vectors incorporating any defined genomic
locus represents a promising advance in the development
of HAC vector technology.
Results
Assembly of linear, prefabricated HAC vectors
The bimolecular BAC-based HAC vector system is com-
prised of a centromere-containing "CEN arm" containing
an 86 kb D17Z1-derived synthetic alpha-satellite array [5]
and a "GEN arm", incorporating a defined, large (>100
kb) genomic fragment. Both BAC-CEN and BAC-GEN
additionally contain ~800 bp synthetic telomeres [15]
and selectable markers as indicated in Figure 1. A linear-
ized CEN arm is generated by digestion of BAC-CEN with
the ultra-rare homing endonucleases I-CeuI and PI-SceI,
which creates a unique, non-self complementary
overhang.
Any genomic BAC vector may be retrofitted to form a
BAC-GEN vector by transposition with a custom-built Tn5
based transposon [27] incorporating a telomere, selecta-
ble markers and appropriately oriented recognition sites
for I-CeuI and PI-SceI [3]. Transposition of the telomere
cassette is non-site specific, and insertions into either the
BAC vector backbone or genomic insert can be isolated.
We were able to generate vector backbone transpositions
for all VJ104-based genomic BACs (generated by "shot-
Strategy for construction of a bimolecular, prefabricated, linear HAC vector Figure 1
Strategy for construction of a bimolecular, prefabricated, linear HAC vector. Digestion of BAC-CEN and BAC-
GEN vectors with the ultra-rare homing endonucleases I-CeuI and PI-SceI permits directional ligation of both "arms" to form a 
linear HAC vector.
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gun" subcloning, see Methods) and genomic transposi-
tions for BACs containing the HGH, PKD1 and ß-globin
loci. For the latter, the integration site of the transposon
was established by direct sequencing, and the transposon
was confirmed to not interrupt either the target gene or its
established regulatory elements (data not shown).
The BAC-GEN arm is linearized in a similar manner to
BAC-CEN, generating an overhang that is complementary
only to the residual PI-SceI overhang created from the
CEN arm. A ligation between the linearized CEN and GEN
arms generates a prefabricated, linear HAC vector (Figs.
1,2), which may be gel-purified and introduced into
mammalian cells by transfection or direct nuclear micro-
injection; alternatively, the entire ligation reaction may be
transfected directly.
We assembled a collection of thirteen BAC-GEN vectors
representing different genomic loci (100–200 kb) that
were shotgun subcloned or identified through the public
databases as containing genes of potential therapeutic
interest (see Methods). A summary of the sizes and chro-
mosomal origins of each of these genomic fragments is
indicated in Table 1. Prefabricated HAC vectors contain-
ing each of these genomic loci were generated by the
methodology described in Figures 1 and 2 and transfected
into HT1080 cells, resulting in the formation of large,
cytogenetically visible de novo HACs presumably com-
posed of concatamers of the initial DNA species. Assem-
bly of the prefabricated HAC was monitored in all cases by
PFGE or FIGE (Fig. 2) (see Methods for additional
details).
Impact of different genomic loci on de novo HAC 
formation
The efficiency of de novo HAC formation from prefabri-
cated HAC vectors containing different genomic loci is
summarized in Table 1. All HACs were validated structur-
ally by FISH analysis with probes against D17Z1 alpha-
satellite, BAC vector, genomic insert and telomeric DNA,
as shown in Figure 3A–C. De novo centromere formation
was demonstrated by the localization of CENP-C to the
HAC (Figure 3D); CENP-C is an established marker of
functional centromeres [28,29]. Although the numbers of
clones are modest, it is clear from the data in Table 1 that
not all the genomic loci examined form HACs at similar
efficiency. For example, some genomic loci (e.g. G2, G17
and G19) form HACs only rarely (<10%). In contrast,
fragments G6 (75%) and G16 (71%) appear to facilitate
de novo HAC formation much more efficiently. Fragment
G6 is a 101,704 bp NotI fragment represented on the
genome scaffold by BAC accession numbers AC004854.2
and AC004847.3. Fragment G16 is a 84,886 bp NotI frag-
ment represented on the genome scaffold by BAC acces-
sion numbers AC104698 and AC016907. Other loci,
including the HGH and PKD1 genomic loci, form HACs
at intermediate frequencies (19% and 21%, respectively).
Interestingly, the HGH locus in a prefabricated vector
Pulsed Field Gel Electrophoresis showing creation of HAC vector Figure 2
Pulsed Field Gel Electrophoresis showing creation of HAC vector. Ligation reactions were set up using linearized 
BAC-CEN alone (Lane 1), linearized BAC-GEN alone (Lane 2), or linearized BAC-CEN and BAC-GEN together (Lane 3). A 
clear ligation product (arrow), the linear HAC vector, is only visible in Lane 3. Note that trace amounts of re-circularized CEN 
and GEN arms are detectable in Lanes 1 and 2, but these do not significantly affect assembly or purification of the HAC.
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formed HACs at approximately the same frequency as
reported earlier for the same locus in a different vector sys-
tem [3], suggesting that this intermediate frequency is
indeed a property of the genomic locus.
Functionality of ß-globin HAC vectors
It is important to determine whether genes introduced as
part of HAC vectors are functional in the recipient host
cell. As a proof of principle, we have generated evidence of
sustained gene expression from cytogenetically validated
HACs containing the entire 200 kb ß-globin genomic
locus, establishing the potential application of future iter-
ations of these HACs for gene transfer. As shown in Figure
4, expression from the third exon of ß-globin is continu-
ously detectable by RT-PCR from clones containing ß-
globin HACs after 30 days of culture in the absence of
selective pressure in the cell line HT1080, a fibrosarcoma
line that does not express ß-globin. Expression of ß-globin
continues to be detectable in the absence of selection for
>90 days of continuous culture (data not shown).
Discussion
Design and validation of bimolecular BAC-based HAC 
vectors
HACs are believed to function by reproducing the three
known critical elements of naturally occurring chromo-
somes: centromeres, telomeres and origins of replication
[1,2]. Optimization of HAC formation may theoretically
be achieved by the systematic identification and manipu-
lation of factors that affect the efficiency of formation and
subsequent stability of each of these key functional ele-
ments. For example, in previous studies, we and others
have used de novo centromere formation as an assay to
design and evaluate synthetic D17Z1-based alpha-satellite
arrays with modifications in the density and distribution
of the consensus CENP-B box, a protein binding site
known to impact the effectiveness of de novo centromere
formation [3,30]. We have shown that D17Z1-based
arrays containing an increased number of CENP-B boxes
relative to native D17Z1 show a corresponding increase in
the efficiency of de novo HAC assembly [3].
In this report, we employ de novo HAC formation as an
assay to identify genomic loci that are highly efficient in
HAC formation and are thus candidates for containing
origins of replication, S/MARs or other cis-acting func-
tional elements that may impact the formation and/or
maintenance of HACs. We assembled a collection of
genomic DNAs in the 100–200 kb size range (a size range
providing a reasonable expectation of containing at least
one of these functional units [21]) and assayed their abil-
ity to support the formation of de novo HACs.
Construction of multiple BAC-based HACs demands the
development of novel BAC modification methodologies,
owing to the difficulties inherent in the manipulation of
high-molecular weight DNAs by traditional subcloning
techniques [23]. A first step towards achieving eventual
defined composition of matter for HAC vectors [2]
requires moving away from uncontrolled in vivo mecha-
nisms for HAC vector assembly [5,6,8] towards construc-
tion of pre-fabricated HAC vectors containing clearly
defined centromeric and other genomic elements. The
controlled and systematic generation of large synthetic or
naturally derived alpha-satellite arrays is itself difficult,
but manageable [3,5,30,31]. Once derived however, these
alpha-satellite arrays must be efficiently and predictably
brought together with the genomic fragment of interest to
create a prefabricated HAC vector.
A number of in vivo site-specific recombination
approaches to join large alpha satellite arrays with large
Table 1: Influence of different genomic loci on de novo HAC formation
Genomic Locus Size (kb) Location No. Transfections Freq. HAC formation1
G2 100 9q33 12 1/21 (5%)
G4 98 8q24.3 10 8/19 (42%)
G6 90 7p13 6 9/12 (75%)
G8 125 15q23 5 1/8 (12%)
G10 125 3p16 9 3/16 (19%)
G11 100 22q11.4 11 9/33 (27%)
G14 125 1q32 2 3/14 (21%)
G16 97 2p23 5 5/7 (71%)
G17 97 4q22 8 2/19 (10%)
G19 95 11p13 6 1/26 (4%)
ß-globin 216 11p15.5 6 7/27 (26%)
HGH 159 17q24.2 8 3/16 (19%)
PKD1 208 16p13.3 10 4/19 (21%)
1: HAC formation frequency is listed as (# clones containing HAC functionally validated by cytogenetic analysis and mitotic stability for at least 90 
days)/(Total # clones screened from all transfections with the genomic locus of interest)BMC Biotechnology 2005, 5:21 http://www.biomedcentral.com/1472-6750/5/21
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genomic fragments have been reported [32,33], involving
multi-step recombinogenic methodologies whose limita-
tions are evidenced by the fact that few genomic loci have
to date been reported to have been successfully incorpo-
rated into a HAC vector. In contrast, our transposon-based
strategy for the construction of bimolecular BAC-based
HAC vectors has facilitated the high-throughput creation
of de novo HACs from multiple large genomic loci. Addi-
Cytogenetic validation of de novo HAC vectors containing the ß-globin genomic locus Figure 3
Cytogenetic validation of de novo HAC vectors containing the ß-globin genomic locus. A) D17Z1 alpha-satellite 
(green), BAC vector (red). (B) D17Z1 alpha-satellite (green), ß-globin genomic locus (red). (C) D17Z1 alpha-satellite (green), 
telomere DNA (red). (D) D17Z1 alpha-satellite (green), CENP-C (red). In all cases, DNA is in blue (DAPI). Arrows point to de 
novo HACs.BMC Biotechnology 2005, 5:21 http://www.biomedcentral.com/1472-6750/5/21
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tionally, our laboratory has recently reported a comple-
mentary transposon-based methodology for the rapid
retrofitting of genomic BACs into unimolecular BAC-HAC
vectors, by the mobilization of a single transposable ele-
ment containing alpha-satellite, telomeric DNA and
mammalian selectable markers [3]. This latter approach
may be even more efficient overall, avoiding the require-
ment for an in vitro ligation between two distinct DNA
species and providing the flexibility to create either
circular or linear derivatives of the same BAC-HAC vector
as needed [3].
On the other hand, the strategy detailed in the current
report involves modification of a target genomic BAC with
a much smaller transposable element, enabling the retro-
fitting of the target BAC with the desired functional cas-
settes to be achieved in a more straightforward and
efficient manner. However, we cannot rule out the possi-
bility that trace amounts of recircularized CEN or GEN
arms (Figure 2) are co-purified with the prefabricated spe-
cies and contribute to de novo HAC formation, or, if the
entire ligation reaction is used, determine to what extent
individual, linearized CEN or GEN arms contribute to de
novo HAC assembly by end-joining or non-homologous
recombination mechanisms [5]. Given that the resultant
de novo HACs are ultimately produced by the uncontrolled
concatamerization of the starting DNA species, this point,
while noteworthy, is not significant in our view.
It is important to view the current strategy attempting to
create prefabricated HAC vectors in the context of iterative
progress towards the eventual achievement of defined
composition of matter for de novo HACs, while under-
standing that this remains a goal yet to be accomplished
Analysis of ß-globin mRNA expression from cell lines containing de novo ß-globin HACs after 30 days in the absence of  selection Figure 4
Analysis of ß-globin mRNA expression from cell lines containing de novo ß-globin HACs after 30 days in the 
absence of selection. Poly A+ RNA from individual cell clones was subjected to first strand synthesis and PCR with primers 
specific to exon-3 of the ß-globin gene. Arrow indicates the ß-globin PCR product. 1) Untransfected HT1080. (2) Untrans-
fected HT1080, no reverse transcriptase (RT). (3) ß-globin HAC clone #1, +RT. (4) ß-globin HAC clone #1, -RT. (5) ß-globin 
HAC clone #2, +RT. (6) ß-globin HAC clone #1, -RT. (7) ß-globin genomic DNA control
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[2]. Only when this objective has been reached will dissec-
tion of the relative contributions of "contaminating" alter-
native forms of the starting vectors be truly meaningful.
Nevertheless, the overall effectiveness of the current meth-
odology has facilitated the construction and functional
validation of multiple de novo HACs derived from a signif-
icant collection of genomic loci, thereby establishing HAC
technology as a general one suitable for analysis of in
principle any locus in the genome.
cis-acting genomic loci affect de novo HAC formation
Although the current study was initiated to provide a func-
tional platform for the identification of functional
genomic elements in a manner analogous to that first
used to identify Autonomously Replicating Sequences
(ARS elements) in yeast [17], we stress that we currently
have no independent biochemical or other confirmation
that the observed effects on HAC formation frequencies
are actually related to the presence or absence of replica-
tion origins, S/MARs or any other specific functional ele-
ments. Nevertheless, it is not unreasonable to propose
variation in origin function as one hypothesis to explain
the observed differences in de novo HAC assembly, and
further experiments will be required to explore this
possibility.
As seen in Table 1, the majority of genomic fragments sur-
veyed support de novo HAC formation at frequencies con-
sistent with previous reports using vectors that lack
genomic fragments or contain a limited number of other
genomic fragments [3,4,16,34]. Indeed, our own previous
results using BAC vectors containing only the synthetic,
86 kb D17Z1-based alpha-satellite array used in the cur-
rent report generates a baseline for de novo HAC formation
of 10.5% from 38 analyzed clones [3]. The majority of
genomic fragments surveyed (G2, G8, G10, G14, G17,
G19) appear to support de novo HAC formation at fre-
quencies comparable to alpha-satellite alone [3]. We note
that the unimolecular BAC-HAC vector reported in [3]
incorporating the same HGH genomic region used in the
current report forms de novo HACs at similar intermediate
frequencies comparable to that observed here (15% in [3],
19% in the current report). Other genomic loci (G4, G6,
G11, G16 and the ß-globin locus) do appear to facilitate
de novo HAC formation at efficiencies above the baseline
(see Table 1). Most notably, genomic loci G6 and G16
support de novo HAC formation at frequencies of over
70%, substantially higher than other genomic fragments
of similar size. These effects clearly cannot be explained as
the result of a simple increase in the size of the HAC vec-
tor, as this would result in a general increase in de novo
HAC formation regardless of which specific genomic frag-
ment was utilized. Further dissection of these 100 kb frag-
ments is currently underway to isolate smaller
subfragments that may be incorporated as a functional
cassette into the design of future iterations of HAC vectors.
Cell line specific effects on de novo HAC formation and 
gene expression
The current report is based on the analysis of de novo HAC
formation in the HT1080 fibrosarcoma cell line, consist-
ent with all previously reported studies on the assembly of
de novo HACs (reviewed in [1,2]). Although no systematic
examination of the role of the host cell environment on
rates of de novo HAC formation has yet been reported, it
remains formally possible that the cis-acting effects of
adjacent genomic loci on de novo HAC formation are con-
tingent on certain cellular environments. Although the
choice of the HT1080 cell line for use in this and other
related studies [1,2] is largely historical, we have observed
comparable rates of de novo HAC formation in the 293
and other closely related cell lines using BAC vectors con-
taining only cloned alpha-satellite DNA (our unpublished
observations).
The observation that de novo HACs incorporating a 216 kb
ß-globin genomic locus do in fact express ß-globin in the
non-erythroid HT1080 cell line is noteworthy (Figure 4).
Although these HACs contain the entire 5' and 3' Locus
Control Regions established as being critical for the regu-
lation of globin gene expression in a physiologically
appropriate manner [37], it appears that the cloned ß-
globin genomic DNA, upon introduction into the cell
nucleus in the context of a HAC vector, does not adopt the
repressive chromatin configuration found at the endog-
enous, host cell ß-globin locus. This observation may
potentially be highly significant if found to be consistent
with the behavior of additional genes upon introduction
into the nucleus as HAC vectors, as it impacts on the abil-
ity to reproducibly and reliably obtain cell- and tissue spe-
cific-patterns of gene expression for applications in
biotechnology. Finally, although we have not rigorously
quantified ß-globin gene expression from clones contain-
ing de novo ß-globin HAC vectors over time, we do note
that ß-globin gene expression is stably observed by the RT-
PCR assay of Figure 4 over the 90-day time period used in
the current report (data not shown).
Conclusion
HAC vectors provide a novel approach to human genome
annotation and gene transfer that may ultimately circum-
vent many of the technical difficulties currently associated
with standard, retroviral-based gene therapy vectors [2].
These include position effects on gene expression and
transgene silencing (reviewed in [35]) and a strict, upper
packaging limit permitting delivery of only about 8 kb of
foreign DNA [36], precluding the incorporation of critical
genomic elements that may be required for physiologi-
cally meaningful expression of a therapeutic transgeneBMC Biotechnology 2005, 5:21 http://www.biomedcentral.com/1472-6750/5/21
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[37]. Additionally, integration of viral vectors into the
host genome has been shown to result in oncogene acti-
vation leading to cancer [38]. Finally, viral vectors used in
recent clinical trials have resulted in severe immunologi-
cal reactions and death [39].
In contrast to the capacity limits of conventional gene
transfer vectors, we have been able to design and construct
HAC vectors that contain the entire 200 kb ß-globin
genomic region, including the 5' Locus Control Region
required for ß-globin gene regulation and expression [37],
thereby bypassing the requirement to identify, dissect and
repackage critical regulatory elements into mini-genes
capable of being delivered by potentially immunogenic
viral vectors. We have shown sustained gene expression
from these ß-globin HACs in the absence of selective pres-
sure during at least 90 days of continuous culture. Simi-
larly, we have designed and fabricated HAC vectors
incorporating the entire HGH (159 kb) and PKD1 (208
kb) genomic loci; the PKD1 cDNA itself is over 14 kb, well
outside the range of retroviral gene therapy vectors [40].
In summary, we anticipate that the functional identifica-
tion and optimization of individual chromosomal com-
ponents using the HAC vector systems described here and
elsewhere [2,3] will eventually permit the design and con-
struction of prefabricated, custom built HAC vectors
incorporating any therapeutic gene in the context of its
full complement of endogenous, genomic regulatory ele-
ments. HAC vectors may therefore not only fulfill their
potential in biotechnology, but will additionally lead to
significant advances in the functional annotation of the
genome.
Methods
Construction of BAC-CEN and BAC-GEN
BAC-CEN is a derivative of pBAC108L, modified to
include ~800 bp of synthetic telomeric sequence (made as
described in [5]), a puromycin resistance cassette and an
adapter containing the recognition sites for the homing
endonucleases I-CeuI and PI-SceI (New England Biolabs).
86 kb of synthetic, D17Z1-based alpha-satellite DNA
(representing 32 tandem copies of the 2.7 kb higher-order
repeat) was subcloned as a BamHI-BglII fragment into a
unique BamHI site on BAC-CEN, to create BAC-
CEN17a32.
Individual BAC-GEN vectors were generated by transpo-
son-mediated retrofitting of defined, genomic BACs [27].
To create the transposon targeting vector, the EZ:TN trans-
poson (Epicentre Technologies, Madison WI) was modi-
fied to include ~800 bp of synthetic telomeric DNA, a
neomycin/kanamycin resistance marker and an adapter
containing the recognition sites for the homing endonu-
cleases I-CeuI and PI-SceI, as described above. Transposi-
tion reactions were carried out as recommended by the
manufacturer. Target genomic BACs were identified and
procured through the genome project databases (PKD1:
CTD2517G10-208 kb, ß-globin: CTD264317-216 kb,
HGH: CTD2202F23-159 kb, all obtained from Research
Genetics), or were created by "shotgun" subcloning of
size-selected, NotI-digested whole genomic DNA into the
BAC vector VJ104, a pBAC108L derivative [5]. Transposi-
tion of the telomeric unit into the vector backbone of a
genomic BAC was identified as an upward shift in the elec-
trophoretic mobility of the corresponding vector band
upon digestion with NotI (data not shown).
Preparation of the prefabricated HAC vector
10 µg (equimolar amounts) of each of BAC-CEN and the
selected BAC-GEN DNAs were mixed together into a sin-
gle 1.5 ml eppendorf tube and digested with PI-SceI and I-
ceuI in a total volume of 200 µl for 3 hours. The homing
endonucleases were heat inactivated, and ATP (Epicentre)
was added to a final concentration of 1 mM. The linear-
ized CEN and GEN arms were ligated together overnight
at room temperature by addition of T4 DNA Ligase (New
England Biolabs). In all cases, the assembly of the prefab-
ricated HAC vector was monitored by resolution of the
individual species within the ligation reaction using
Pulsed Field Gel Electrophoresis (PFGE) (Bio-rad, DR-III),
or Field Inversion Gel Electrophoresis (FIGE) (Bio-rad)
and confirmed to have proceeded efficiently as shown in
Figure 2. Only ligation reactions showing efficient assem-
bly of the prefabricated HAC vector were used for transfec-
tions. The ligation product representing the prefabricated
vector species could then be gel purified by electroelution
of the target band out of the gel slice into 0.5X TBE. The
electroeluted DNA species was then dialyzed into ddH2O
and concentrated into the smallest possible volume using
a Microcon YM-100 spin column (Amicon) according to
the manufacturer's instructions. The concentrated HAC
vector was used directly for transfection as described
below. In some cases, the ligation reaction was transfected
directly without additional gel-purification of the prefab-
ricated species.
Cell transfection
Human fibrosarcoma HT1080 cells were transfected using
the Fugene-6 (Roche) reagent according to the manufac-
turer's instructions, and stable clones identified through
resistance to puromycin at 3 µg/ml and neomycin at 600
µg/ml. Clones appeared after 7–10 days and were subse-
quently expanded to generate clonal lines for further anal-
ysis. Multiple independent transfections were performed
for all 13 HAC species, and the data pooled to generate
Table 1.BMC Biotechnology 2005, 5:21 http://www.biomedcentral.com/1472-6750/5/21
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Cytogenetic analysis
FISH analysis of clonal lines was carried out according to
established procedures. Briefly, a D17Z1-specific alpha-
satellite probe was used to initially identify putative
HACs. Further structural confirmation of all putative
HACs was done by FISH with probes specific to the BAC
vector backbone, the genomic insert and telomeric DNA.
In all cases, probes were labeled by nick translation in the
prescence of Spectrum Green or Spectrum Orange conju-
gated dUTP (Vysis). For immunofluorescence analysis,
slides were immunoreacted with a rabbit anti-CENP-C
antibody [5] at a concentration of 1/2000 in PBS and
detected with FITC conjugated goat anti-rabbit IgG
(Molecular Probes). Images were acquired through a Zeiss
fluorescence microscope and CCD camera. Clones con-
taining cytogenetically confirmed HACs were further vali-
dated by additional cytogenetic examination following
continuous culture in the absence of selection for at least
90 days (data not shown).
Gene expression
RT-PCR reactions to assay ß-globin gene expression were
carried out using the ExpressDirect system (Pierce) accord-
ing to the manufacturer's instructions. RNA was prepared
from HT1080 cells and HAC-containing clones, using
standard techniques.
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